Sugi Predict

Sugi Predict / Compounds / SCHEMBL4355848

SCHEMBL4355848

SCHEMBL4355848

O=C1Nc2ccc(Br)cc2C12NN=C(c1ccccc1)S2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ADAMTS5 Q9UNA0 17/20 1.00
▸ SLC27A2 O14975 1/20 1.00
▸ SMN1; SMN2 Q16637 4/20 0.69
▸ ALDH1A1 P00352 3/20 0.69
▸ LMNA P02545 3/20 0.69
▸ MEN1 O00255 3/20 0.69
▸ KMT2A Q03164 3/20 0.69
▸ MAPT P10636 3/20 0.69
▸ HTT P42858 3/20 0.69
▸ TDP1 Q9NUW8 3/20 0.69
▸ L3MBTL1 Q9Y468 3/20 0.69
▸ HPGD P15428 3/20 0.69
▸ MAPK1 P28482 2/20 0.69
▸ XBP1 P17861 1/20 0.69
▸ MDM2 Q00987 1/20 0.69
▸ KDM4E B2RXH2 2/20 0.55
▸ TP53 P04637 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12315873 0.86 ADAMTS5 (0.76) ADAMTS5SLC27A2SMN1; SMN2ALDH1A1LMNA
SCHEMBL4201238 0.85 ADAMTS5 (1.00) ADAMTS5SLC27A2SMN1; SMN2ALDH1A1LMNA
SCHEMBL24571274 0.85 ADAMTS5 (0.74) ADAMTS5SLC27A2SMN1; SMN2ALDH1A1LMNA
SCHEMBL4354096 0.85 ADAMTS5 (1.00) ADAMTS5SLC27A2SMN1; SMN2ALDH1A1LMNA
SCHEMBL24571119 0.85 ADAMTS5 (0.74) ADAMTS5SLC27A2SMN1; SMN2ALDH1A1LMNA
SCHEMBL4983286 0.84 ADAMTS5 (1.00) ADAMTS5SLC27A2SMN1; SMN2ALDH1A1LMNA
SCHEMBL12315860 0.84 ADAMTS5 (0.72) ADAMTS5SLC27A2SMN1; SMN2ALDH1A1LMNA
SCHEMBL22571281 0.82 ADAMTS5 (0.70) ADAMTS5SLC27A2SMN1; SMN2ALDH1A1LMNA
SCHEMBL22571267 0.82 ADAMTS5 (0.70) ADAMTS5SLC27A2SMN1; SMN2ALDH1A1LMNA
SCHEMBL4982831 0.82 ADAMTS5 (0.70) ADAMTS5SLC27A2SMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032584-A2 THIADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF Wyeth (US) 2009-03-11 — — EP claimed
US-20080125469-A1 Thiadiazole compounds and methods of use thereof WYETH (US) 2008-05-29 — — US claimed
WO-2007146138-A2 THIADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF WYETH (US) 2007-12-21 — — WO claimed
WO-2005092304-A2 ANTIFUNGAL AGENTS F2G LTD (GB) 2005-10-06 — — WO claimed
EP-4543440-A1 FATP2 IN T CELLS AS A TARGET MOLECULE FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen (DE) 2025-04-30 — — EP disclosed
WO-2023247607-A1 FATP2 IN T CELLS AS A TARGET MOLECULE FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN RHEINISCH-WESTFÄLISCHE TECHNISCHE HOCHSCHULE (RWTH) AACHEN (DE) 2023-12-28 — — WO disclosed
US-20220096484-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER BY TARGETING FATP2 AND MYELOID DERIVED SUPPRESSOR CELLS THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY 2022-03-31 — — US disclosed
US-8431582-B2 Inhibitors of fatty acid uptake and methods of use NUTECH VENTURES (US) 2013-04-30 — — US disclosed
US-8431582-B2 Inhibitors of fatty acid uptake and methods of use NUTECH VENTURES (US) 2013-04-30 — — US disclosed
US-8410118-B2 Inhibitors of fatty acid uptake and methods of use NUTECH VENTURES (US) 2013-04-02 — — US disclosed
US-8410118-B2 Inhibitors of fatty acid uptake and methods of use NUTECH VENTURES (US) 2013-04-02 — — US disclosed
US-20120309772-A1 INHIBITORS OF FATTY ACID UPTAKE AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH 2012-12-06 — — US disclosed
US-20120302585-A1 INHIBITORS OF FATTY ACID UPTAKE AND METHODS OF USE Nutech Ventures, a Nebraska corporation 2012-11-29 — — US disclosed
US-8263640-B2 Inhibitors of fatty acid uptake and methods of use NUTECH VENTURES (US) 2012-09-11 — — US disclosed
US-8263640-B2 Inhibitors of fatty acid uptake and methods of use NUTECH VENTURES (US) 2012-09-11 — — US disclosed
US-20100305106-A1 INHIBITORS OF FATTY ACID UPTAKE AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-12-02 — — US disclosed
US-20100305106-A1 INHIBITORS OF FATTY ACID UPTAKE AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-12-02 — — US disclosed
EP-2032584-A2 THIADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF Wyeth (US) 2009-03-11 — — EP disclosed
US-20080125469-A1 Thiadiazole compounds and methods of use thereof WYETH (US) 2008-05-29 — — US disclosed
WO-2007146138-A2 THIADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF WYETH (US) 2007-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305106-A1 INHIBITORS OF FATTY ACID UPTAKE AND METHODS OF USE SLC27A2, SLC27A1, FABP4 ADAMTS5 3277/4885SLC27A2 1/4885SMN1; SMN2 4342/4885
US-20120302585-A1 INHIBITORS OF FATTY ACID UPTAKE AND METHODS OF USE SLC27A2, SLC27A1, FABP4 ADAMTS5 3277/4885SLC27A2 1/4885SMN1; SMN2 4342/4885
US-20080125469-A1 Thiadiazole compounds and methods of use thereof ADAMTS5, ADAMTS1, TIMP3 ADAMTS5 1/4885SLC27A2 4766/4885SMN1; SMN2 876/4885
US-20120309772-A1 INHIBITORS OF FATTY ACID UPTAKE AND METHODS OF USE SLC27A2, SLC27A1, FABP4 ADAMTS5 3277/4885SLC27A2 1/4885SMN1; SMN2 4342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.